Voyageur Pharmaceuticals Engages Fluor for Feasibility Studies on North America's First Vertically Integrated Contrast Media Supply Chain
核心洞察
Voyageur Pharmaceuticals has engaged Fluor Corporation (搜索) to conduct dual feasibility studies for an iodine extraction facility in Oklahoma and an integrated contrast drug manufacturing plant.
The iodine project, developed in collaboration with Bayer AG, will use Voyageur's patent-pending Mueller process to extract high-purity iodine from oilfield brine.
Voyageur has budgeted US$2,350,000 for the Bayer-linked feasibility study, with both studies expected to complete in early 2027, enabling a potential construction decision that year.
Voyageur Pharmaceuticals Ltd. (搜索) (TSX.V: VM), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, announced on June 23, 2026 that it has engaged Fluor Corporation (搜索), a leading global engineering, procurement, construction and maintenance firm, to complete comprehensive feasibility studies for two strategic projects advancing a vertically integrated North American supply chain for radiology contrast drugs.
The engagement covers two parallel initiatives: a feasibility study for a proposed iodine extraction and production facility in Oklahoma, USA, conducted as part of Voyageur's collaboration with Bayer AG; and a feasibility study for Voyageur's planned pharmaceutical manufacturing plant that will produce finished barium and iodine-based contrast media products.
Iodine Extraction Collaboration with Bayer
The Oklahoma iodine project will utilize Voyageur's patent-pending Mueller process, developed in collaboration with Bayer AG under a milestone-based funding agreement announced on February 23, 2026. The process aims to produce high-purity iodine from iodine-rich oilfield brine for use in contrast media drugs. Voyageur has budgeted US$2,350,000 for completion of the Bayer project feasibility study.
Subject to successful completion of the feasibility study and further agreement of the parties, Voyageur and Bayer may consider advancing the project into a subsequent phase under an offtake-linked production financing arrangement. In a potential subsequent phase, Bayer may provide capital financing for the project, while Voyageur would operate and manage the project, subject to definitive agreements.
Integrated Manufacturing Facility
The second feasibility study focuses on Voyageur's planned integrated iodine and barium contrast drug manufacturing facility. This plant is expected to integrate Voyageur's high-purity barite from its 100%-owned Frances Creek barium deposit in British Columbia with domestically sourced iodine, creating what the company describes as the first fully integrated "Earth-to-Bottle" contrast media platform in North America.
A final budget for the integrated manufacturing facility feasibility study will be established after completion of testing on Voyageur's proprietary Streamline iodine drug manufacturing process.
Timeline and Strategic Significance
Both feasibility studies are expected to be completed in early 2027, paving the way for a potential construction decision later that year. Fluor's expertise in process engineering, project economics, and large-scale industrial facility design is expected to ensure both studies meet the technical, environmental, and economic standards required for project financing and regulatory approvals.
"We are thrilled to partner with Fluor to de-risk and accelerate these projects," said Brent Willis, CEO of Voyageur Pharmaceuticals. "With the iodine initiative and Fluor's technical expertise, we are moving decisively toward securing North America's supply chain for critical medical imaging drugs. These feasibility studies represent a major milestone in our strategy to become the first fully integrated producer of both barium and iodine contrast agents on the continent."
Building on Existing Commercial Momentum
The dual feasibility studies build on Voyageur's recent progress, including Health Canada-approved barium contrast products that are already generating commercial sales in Canada. The company has developed five barium contrast products holding Health Canada licenses and currently generating revenue.
Voyageur's end-to-end ownership model — from raw material extraction through proprietary processing to finished pharmaceutical products — is expected to deliver materially lower operating costs than competitors who purchase intermediates on the open market. The company also anticipates that its integrated supply chain will create a reliable, North American-based source for critical medical imaging agents, significantly reducing geopolitical, logistics, and shortage risks for hospitals and patients in the United States and Canada.